Nutraceuticals / Health food
Primarily generic pharmaceuticals. Strategy is to provide niche and high manufacturing complexity API and generic drugs, as well as 505(b)(2) class new drugs (new route of administration, new derivatives, new use, etc.).
Six manufacturing facilities in Taiwan.
Affiliates include:
Chunghwa Chemical Synthesis & Biotech Co., Ltd.: API manufacturer
Suzhou Chunghwa Chemical & Pharmaceutical Industrial Co., Ltd. (China)
Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd. (China)
Chunghwa Yuming Healthcare Co., Ltd. (drug distribution)
Chunghwa Senior Care Co., Ltd. (seniors health care services)
Phermpep Co., Ltd. (peptide-based products for health)
Tai Rung Development Co., Ltd. (packaging products, ampoules, etc.)
Botanical drug development, botanical healthcare and cosmetics products.
Producer of API, probiotics and other health products. OEM/ODM services. Also in agricultural sector, producing feed additives.
Products include pharmaceuticals, cancer drugs, cosmeceuticals, infant & adult nutrition and healthcare products.
Nangang Dist, Taipei 115,
Taiwan
New drug development in analgesics, cold remedies, gastrointestinal drugs, urinary system drugs, skin disease remedies. Also cosmeceuticals and nutritional products. Lead product is kidney drug Nephoxil, sold in the US as Auryxia under USFDA authority by Keryx Biopharmaceuticals Inc. Also sold in Japan.
Developer of botanically-derived drugs, also some health food products
First drug development company listed on the Taiwan stock market, back in 2008.
Member of the Maywufa Group, involved in health products, drug distribution, etc.
Built Taiwan’s first GMP sterile botanical drug manufacturing facility in compliance with PIC/S and FDA regulations.
Success story is ‘PG2’ lyophilized injection, approved by the TFDA for fatigue in cancer patients, and currently undergoing FDA Phase II trial for the same.
Other drugs in the pipeline include:
PHN131 (for moderate to severe pain)
PHN014 (for acute ischemia stroke)
PHN031 (for osteoporosis prevention)
PHN033 (for diabetic nephropathy treatment)
PHN015 (for hemorrhage stroke)
PHN013 (for idiopathic thrombocytopenic purpura (ITP))
PHDC-01 (stem cell treatment for bone growth)
PHDC-02 (stem cell treatment for cartilage growth)
Generic drug company, also OTC products, dietary supplements and medical devices (Bipolysorb, a bone filler).
Focus on drug delivery technologies, including peptide delivery systems, liposome technology, SR formulation, and orally disintegrating dosage technology.
Pharmaceuticals, new drugs, botanical drugs, nutrition and healthfood products. PIC/s GMP, ISO 9001, ISO 17025, ISO 14001, ISO 22000, and OHSAS 18001 pharmaceutical company in Taiwan
Generic drug manufacturer. Also veterinary products and health foods / supplements.